Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
第一著者: | |
---|---|
その他の著者: | |
フォーマット: | 学位論文 |
言語: | English |
出版事項: |
Brac University
2024
|
主題: | |
オンライン・アクセス: | http://hdl.handle.net/10361/22868 |
id |
10361-22868 |
---|---|
record_format |
dspace |
spelling |
10361-228682024-06-09T09:20:26Z Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study Tabassum, Nadira Yasmin, Hasina School of Pharmacy, Brac University Pharmacovigilance Alzheimer disease Dementia Rhabdomyolysis Alzheimer's disease Dementia This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from PDF version of thesis. Includes bibliographical references (pages 37-41). Alzheimer’s disease is a neurodegenerative disease. Using FDA Adverse Event Reporting System database, a pharmacovigilance study for gender specific rhabdomyolysis risk in memantine users was conducted between January 2016-June 2023. “R” statistical tool was used to calculate the reporting odds ratio (95%CI), which serves as a signal index. Memantine showed a signal, when the whole dataset is used as a comparator, but not when AChEIs are used. ROR,95% CI value for male memantine consumers 5.68 (2.12 - 15.19), for female 7.98 (2.55-24.70) while using whole dataset as comparator. Again, male patients value is 1.40 (0.46 - 4.26), whereas 2.53 (0.65 - 9.83) for females, using AChEIs as comparator. Females have a higher risk of developing rhabdomyolysis than males as the ROR value was higher for them in both comparisons. Thus, data shows memantine has a safer, more acceptable profile than AChEIs & can be considered in comparison to other options. Nadira Tabassum B. Pharmacy 2024-05-19T08:17:32Z 2024-05-19T08:17:32Z ©2023 2023-10 Thesis ID 19346012 http://hdl.handle.net/10361/22868 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 61 pages application/pdf Brac University |
institution |
Brac University |
collection |
Institutional Repository |
language |
English |
topic |
Pharmacovigilance Alzheimer disease Dementia Rhabdomyolysis Alzheimer's disease Dementia |
spellingShingle |
Pharmacovigilance Alzheimer disease Dementia Rhabdomyolysis Alzheimer's disease Dementia Tabassum, Nadira Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
author2 |
Yasmin, Hasina |
author_facet |
Yasmin, Hasina Tabassum, Nadira |
format |
Thesis |
author |
Tabassum, Nadira |
author_sort |
Tabassum, Nadira |
title |
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
title_short |
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
title_full |
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
title_fullStr |
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
title_full_unstemmed |
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
title_sort |
gender-specific rhabdomyolysis risk in alzheimer’s disease patients receiving memantine: a pharmacovigilance study |
publisher |
Brac University |
publishDate |
2024 |
url |
http://hdl.handle.net/10361/22868 |
work_keys_str_mv |
AT tabassumnadira genderspecificrhabdomyolysisriskinalzheimersdiseasepatientsreceivingmemantineapharmacovigilancestudy |
_version_ |
1814308170837786624 |